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bstract
To face known and emerging threats to public health, all countries have to overcome the challenges of providing sufficient supplies of blood
nd blood products of the highest quality and safety. Unfortunately, self-sufficiency is not yet a reality in many countries. In 2011, experts from
HO addressed the urgent need to establish strategies and mechanisms for achieving this goal. A summary of these recommendations is further
iscussed.
 2013 N. Dhingra. Published by Elsevier Masson SAS. All rights reserved.
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ésumé
Pour faire face aux menaces connues et émergentes de santé publique, tous les pays doivent maîtriser les enjeux d’approvisionnement de sang
t de produits sanguins au plus haut niveau possible de qualité et de sécurité. Malheureusement, l’autosuffisance n’est pas encore une réalité dans
e nombreux pays. En 2011, des experts de l’OMS ont rappelé le besoin urgent de mettre en place des stratégies et des mécanismes permettant
’atteindre ce but. Un résumé de ces recommandations sera discuté.
 2013 N. Dhingra. Publie´ par Elsevier Masson SAS. Tous droits réservés.
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.  Introduction
Blood transfusion services play a central, underpinning role
n health systems by providing safe and adequate supplies
f blood and blood products for patients requiring transfu-
ion (blood products are defined as any therapeutic substances
erived from human blood, including whole blood, labile blood
omponents and blood- or plasma-derived medicinal products
PDMPs]). Availability and safety of blood and blood products
emains a major concern in many countries around the world
nd countries are facing unique challenges in ensuring self-
ufficiency in safe blood and blood products based on voluntary
on-remunerated blood donations (VNRBD)1 [1].
E-mail address: dhingran@who.int
1 Voluntary non-remunerated blood donation also includes the donation of
lasma and cellular blood components.
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Only 62 countries (32%) of 193 WHO Member States report
ollecting 100% or more than 99% of their blood supplies for
hole blood from VNRBD [2]. Typically these are countries in
he higher-income group; where health care systems are more
eveloped and where VNRBD is associated with sufficient sup-
ly and a stable blood donor base. On the other end of the scale,
here are many countries in the world where the supply of blood
nd blood products is insufficient, and where a stable donor
ase is more difficult to achieve. Typically these are countries
n the low- and medium-income group, where supply is met
artly with VNRBD as well as with replacement donors and
aid donors. Clearly the demand for blood and blood products
epends on state of development of the local health care system,
ut in countries where less than 1% of the general population
onates (77 Member States), supply is clearly insufficient to
eet the needs of patients.
Voluntary non-remunerated blood donors are the corner-
tone of a safe and sufficient blood supply and are the first
ine of defense against the transmission of infection through
S. All rights reserved.
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ransfusion. Regular VNRBD from low-risk populations have
epeatedly been demonstrated to have low rates of markers of
IV and other transfusion-transmissible infections (TTIs) than
aid or replacement donors. This has particular significance for
ountries with high burdens of TTIs. The importance of VNRBD
as been reaffirmed by several World Health Assembly resolu-
ions and declarations (including WHA28.72, WHA58.13 and
HA63.12) [3].
.  Self-sufﬁciency  in  safe  blood  and  blood  products
ased on  VNRBD
The issue of self-sufficiency in blood and blood products
enerated much interests and discussion among the Member
tates during the 126th WHO Executive Board (resolution
B126.R14) and the 63rd World Health Assembly adopted the
esolution WHA 63.12 on the ‘Availability, safety and qual-
ty of blood products’. The WHA resolutions, The Melbourne
eclaration on 100% Voluntary Non-Remunerated Donation of
lood and Blood Components (June 2009) [4] and the recom-
endations of the WHO Global Blood Safety Network [5,6]
ave reaffirmed the achievement of self-sufficiency in blood
nd blood products based on VNRBD and the security of that
upply as the important national policy direction for ensur-
ng a safe, secure and sufficient supply of blood and blood
roducts.
WHA 63.12, thereby, urges the WHO Member States
to take all the necessary steps to establish, imple-
ent and support nationally-coordinated, efficiently-managed
nd sustainable blood and plasma programmes according
o availability of resources, with the aim of achieving
elf-sufficiency”.
Despite some successes, self-sufficiency is not yet a real-
ty in many countries. A consultation of experts, convened by
he World Health Organization (WHO) in September 2011 in
eneva, Switzerland, addressed the urgent need to establish
trategies and mechanisms for achieving self-sufficiency. Infor-
ation on the current situation, and country perspectives and
xperiences were shared. Factors influencing the global imple-
entation of self-sufficiency, including safety, ethics, security
nd sustainability of supply, trade and its potential impact on
ublic health, availability and access for patients, were ana-
ysed to define strategies and mechanisms and provide practical
uidance on achieving self-sufficiency. Experts developed a
onsensus statement outlining the rationale and definition of
elf-sufficiency in safe blood and blood products based on
NRBD and made recommendations to national health author-
ties and WHO [7].
.  Expert  Consensus  Statement  on  achieving
elf-sufﬁciency  in  safe  blood  and  blood  products,  based
n voluntary  non-remunerated  blood  donation
VNRBD)  [7]Experts Consensus Statement also defines that self-
ufficiency in safe blood and blood products based on VNRBD
eans that the national needs of patients for safe blood and
t
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lood products, as assessed within the framework of the national
ealth system, are met in a timely manner, that patients have
quitable access to transfusion services and blood products, and
hat these products are obtained from VNRBD of national and,
here needed, of regional origin, such as from neighbouring
ountries.
The Statement also recognizes that six blood products will
ost likely form the drivers for the number of donations of
lood, plasma and cellular blood components needed and these
hould be given priority in policy and strategy development for
chieving self-sufficiency based on VNRBD. These six driver
roducts are:
 whole blood and red blood cells either recovered from whole
blood or by apheresis (WB/RBC);
 platelets either recovered from whole blood or by apheresis
(PLT);
 plasma for transfusion either recovered from whole blood or
sourced by apheresis and prepared by any production method
(FFP);
 plasma-derived clotting factor VIII prepared by any produc-
tion method (pd-FVIII);
 polyvalent human (H) immune globulin (IgIV or IgSC);
 human albumin solutions for transfusion (Alb).
VNRBD means that a person gives blood, plasma or cellular
omponents of his/her own free will and receives no payment
or it, either in the form of cash, or in kind which could be
onsidered a substitute for money. This would include time off
ork other than that reasonably needed for the donation and
ravel. Small tokens, refreshments and reimbursements of direct
ravel costs are compatible with voluntary non-remunerated
onation.
Definition of VNRBD has already been endorsed by the
HO, the International Society of Blood Transfusion, the Coun-
il of Europe, the International Federation of Red Cross and Red
rescent Societies and the International Federation of Blood
onor Associations.
In 1972, Titmuss [8] stated his warning: “If blood is consid-
red in theory, in law, and is treated in practice as a trading
ommodity then ultimately human hearts, kidneys, eyes and
ther organs of the body may also come to be treated as com-
odities to be bought and sold in the marketplace”. It remains
ustomary for countries to supply their own needs of whole
lood (WB) and blood components (BC), usually by VNRBD.
owever, for PDMPs, many countries rely on importing the
nished products. These often originate from plasma obtained
rom donors paid by the fractionation companies, sometimes
ixed with plasma from VNRBD. This challenges the warning
f Titmuss [8]. Reliance on imported products from paid donors
lso is at variance with resolutions, statements and recommenda-
ions from the WHO, the International Red Cross, the Council
f Europe and the International Society of Blood Transfusion
7,9–11].
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.  International  challenges  of  self-sufﬁciency  in  blood
nd blood  products
.1.  Lack  of  clear  national  policy  and  government
ommitment
A lack of a clear policy, vision and government commitment
s one of main challenges in moving towards self-sufficiency
n blood and blood products. In 2008, 75% of countries had a
ational blood policy and 58% of countries had a specific leg-
slation covering the safety and quality of blood transfusion. In
ther words, 25% of countries have no national blood policy and
3% of low-income countries, 39% of middle-income countries
nd 31% of high-income countries have no specific legislation
overing the safety and quality of blood transfusion.
.2.  Increasing  needs  and  demand
The need for safe, efficacious and secure supplies of blood
roducts is universal and projections for supply of blood
nd blood products remain challenging to estimate. As the
nowledge and understanding of human health and medicine
dvance, diagnostic and medical practices advance, this causes
he demand for blood and blood products to increase. Chang-
ng population demographics have also increased the need for
lood transfusion. Globally, more than 70 countries have a blood
onation rate less than the figure generally considered as neces-
ary to meet a nation’s basic requirements for blood, namely 1%
f the population; the requirements are higher in countries with
dvanced health care systems. In some resource-rich countries,
he effects of an increasing age of the population may increase
emand. In resource-limited countries, imbalances in access to
safe) blood components may change as improved access to
ealth care occurs.
The need for blood and blood products is growing every year
nd large numbers of patients who require life-saving support
ith blood and blood products still do not have access to them.
t is therefore essential that all countries have the national capac-
ty to collect blood, plasma and cellular components of optimal
uality and safety from voluntary, non-remunerated donors in
rder to meet the national needs for blood components for trans-
usion and PDMPs. For the supply of PDMPs in particular, in the
ong term it will not be feasible for a small number of countries
o collect sufficient plasma to produce enough PDMPs to meet
lobal needs [7].
.3.  Inadequate  supply  of  blood  and  blood  products
In most countries the estimates of the need for red cells are
sed to set the target for the collection of blood donations. If
here are minor shortfalls, measures are taken to minimize use
ntil demands are met, usually by increased collections. How-
ver for plasma, the recovered plasma (the by-product of whole
lood collections) is usually sufficient to meet the demand for
linical use of plasma, but insufficient to meet the demand for
DMPs. Depending on the country, the response to such a short
all can be to increase the number of plasma collections by
d
T
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lasmapheresis (and in some countries to pay the donors), or
o buy plasma to supplement the domestic supply for fraction-
tion, or to buy PDMPs. To achieve self-sufficiency in plasma
erivatives requires a plasma-driven collection based on plasma-
heresis, which is expensive and results in products that are
ncompetitive with commercial product pricing.
.4.  Decreasing  donor  base
Data from the US, Germany and Japan all showed an ageing
rend in the blood donor pool. There could be more difficulties
n recruiting and retaining adequate number of blood donors,
ffecting the supply of blood and blood products. There is con-
ern that as the population ages, the number of donors will
ecrease. Ageing populations and increasingly stringent donor
election criteria have reduced the pool of eligible donors.
.5.  Failure  to  identify  blood  as  national  resource,  systems
f payment  and  commodiﬁcation  of  blood  products
Blood, plasma and cellular blood components, and other ther-
peutic substances derived from the human body should not be
onsidered as mere ‘commodities’. Donated blood that is pro-
ided voluntarily by healthy and socially committed people is a
recious national resource. Governments should be accountable
or ensuring a sufficient supply of products from these special
esources which are and will remain limited by nature. The avail-
bility and safety of the supply, the safety of both donors and
ecipients and the appropriate use of blood, plasma and cellular
lood donations are and must remain a public affair.
Payment for the donation of blood (including donations of
lasma and cellular components) not only threatens blood safety,
t also erodes community solidarity and social cohesion which,
n the contrary, can be enhanced by the act of voluntary non-
emunerated donation. By placing an onus on under-privileged
opulations in need of money, it also compromises the develop-
ent of a voluntary, non-remunerated blood donor programme.
here are concerns that sufficient safe donations and sustain-
ble supply, availability and access to blood and blood products
ased on VNRBD may be compromised through the presence
f parallel systems of paid donation [7].
The Oviedo Convention on Human Rights and Biomedicine
f 1997 [12] explicitly prohibits any financial gain from the
uman body and its parts. Prevention of the commercialization
f blood donation and exploitation of blood donors are important
thical principles on which a national blood system should be
ased. The right to equal opportunity in access to blood and
lood products of uniform and high quality based on patients’
eeds is rooted in social justice and the social right to health
are.
.6.  Dependence  on  family/replacement  donationsIn many countries, systems based on family/replacement
onation are currently in use for providing blood for patients.
hese systems, however, often lead to coercion and place undue
urden on patients’ families and friends to give blood, also
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eading to systems of hidden payment. Such systems are unreli-
ble, putting the onus for the provision of blood on the patients’
amilies rather than on the health system. In the long term, fam-
ly/replacement donation systems will be unable to provide safe,
ufficient and sustainable national blood supplies, employing
oth component preparation and apheresis donations, to ensure
quitable access for all patients. Such systems will inevitably
ct as a barrier to enabling national blood systems to develop
ppropriately alongside countries’ overall health systems [7].
.7.  Risks  to  donors’  health  and  safety
The long-term effects of frequent large donations of plasma
re not known. However, recent studies have shown signifi-
ant decreases in protein content, particularly immunoglobulins,
ollowing frequent plasmapheresis [13].
.8.  Risk  of  transfusion-transmissible  infections
When rigorous standards for donor recruitment and selection,
onation testing and processing, and clinical transfusion are not
pplied or fail, transfusion of blood products poses a serious
isk of transmission of pathogens. Unfortunately, current sys-
ems for blood and plasma donation, processing and testing are
nadequate in many developing countries. In 2008, as many as
9 countries are unable to screen all donated blood for one or
ore of the infections: HIV, hepatitis B, hepatitis C and syphilis.
imited supply or access to test kits is a common barrier to
creening.
At least 47% of donations in the low-income countries
nd 18% of donations in the middle-income countries are not
creened following basic quality procedures (following docu-
ented standard operating procedures and participation in an
xternal quality assurance scheme). There remains a wide gap
n residual risks of TTIs between developed and developing
ountries, including the emerging economies.
There is a pressing need to introduce and strengthen policies,
trategies, quality assurance and regulations of blood products
n order to minimize these risks. The HIV epidemic and the
utbreak of vCJD have demonstrated that global distributions
f PDMPs or intermediates could increase the risk of global
pread in the event of a new emerging transfusion-transmissible
nfection.
.9.  Limited  capacity  in  production  and  processing
Blood collection rates vary markedly between countries.
round 50% of the total estimated 91.8 million donations are
ollected in high-income countries, but home to about 15% of
he world’s population. Blood component production supports
etter inventory management, but there is a low percentage of
omponent preparation from whole blood collections in most
ow-income countries and some middle-income countries. The
apacity to provide patients with the different blood compo-
ents they require is still limited in low-income countries: 31%
f the blood collected in low-income countries is separated into
t
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omponents, compared with 91% in high-income countries and
2% in middle-income countries.
.10.  Poor  quality  systems  in  developing  countries
The absence of quality systems in blood services is a major
mpediment in ensuring safe blood supplies. The quality and
ffectiveness of blood components depend on careful collection,
esting, processing, labelling, storage and distribution. Con-
traints include lack of national standards, inadequate data and
ocumentation, limited training opportunities and poor quality
ssessment. It can therefore be assumed that blood services in
eveloping countries would likewise benefit from the introduc-
ion and enforcement of the appropriate quality systems and
ransparent inspection procedures.
.11.  Wastage  of  blood
Collection of blood from unsafe and unsuitable donors, its
nadequate storage and transportation, and poor inventory man-
gement lead to the loss of at least five million blood units
very year [2], further limiting availability of blood and blood
roducts.
.12.  Wastage  of  plasma
There is evidence of inefficiencies with variable to high (and
nacceptable) rates of wastage. In most low-income and many
iddle-income countries, large volumes of plasma recovered
rom whole blood donations based on VNRBD, are currently not
sed and are discarded because of concerns that quality require-
ents are not being met for plasma for fractionation for the
anufacture of PDMPs.
.13.  Inappropriate  use  of  blood  and  blood  products
The issues of sufficiency, availability and access cannot be
onsidered in isolation from use of blood. National data on the
se of blood products are limited, but studies suggest that these
roducts are often used inappropriately both in the developed
nd developing countries. Unnecessary transfusions, unsafe
ransfusion practices and errors (particularly at the patient’s bed-
ide) seriously compromise patient safety by exposing patients
o the risk of serious adverse transfusion reactions and TTIs.
nnecessary use also seriously reduces the availability of blood
roducts for patients who are in need. Both over-transfusion and
nder-transfusion can result in substantial morbidity and mor-
ality. Therefore, comprehensive monitoring and evaluation of
he use of blood products and transfusion practices need to be
stablished.
As the evidence base for transfusion medicine advances, there
s an increasing need to ensure that important new research is
mplemented and that practices which are shown to be less effec-
ive (or cost-inefficient or inappropriate) are discontinued. Many
f the methods used to facilitate change in clinical behaviour are
amiliar to hospital health care workers in the field of transfu-
ion medicine. But evidence remains for the wide variation in
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roportion of the population transfused, from 6.9% in Sweden
o 19% in the US. This variation which must include uncertainty
n optimal transfusion practice is marked between resource-rich
nd resource-limited countries.
.14.  Inﬂuence  of  market  force
Additional commercial factors apply for plasma collection
nd fractionation. With merging and vertical consolidation, a
ore limited number of plasma fractionators not only control the
rocessing of plasma into medicinal products but also directly
ontrol the collection of source plasma through their plasma
enters in different countries.
.  Conclusion
The commitment by national governments to self-sufficiency
n safe blood and blood products based on VNRBD, and
 coordinated, integrated and collaborative approach to
olicy development and planning are prerequisites for ensur-
ng the implementation of fully effective national blood
ystems.
It is recognized that the implementation of a policy for
elf-sufficiency in blood and blood products generally fol-
ows a stepwise progression in scope, from whole blood
ransfusions towards blood components for transfusion and
urther towards plasma fractionation, aligned to the state of
evelopment of the national health system. Achieving self-
ufficiency in the supply of blood and blood products from
NRBD and ensuring the security of that supply are important
ational goals and countries may set different timelines in the
chievement of these goals, depending on their health system
evelopment.
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